Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

June 4, 2021 Auto Bot Clinical Trials, KEYTRUDA, Merck, P-III, pembrolizumab, Renal Cell Carcinoma 0

Shots:

  • The P-III KEYNOTE-564 evaluating Keytruda monothx (200 mg, IV, on day1 of each 3wks. cycle for up to 17 cycles) vs PBO in 950 patients with RCC, following nephrectomy & resection of metastatic lesions
  • Results: @ median follow-up of 24.1 mos., 32% reduction in the risk of disease recurrence or death, a favorable trend in OS was observed with 46% reduction in risk of death
  • Keytruda is currently approved in the US, EU & Japan in combination with axitinib as a 1L treatment for advanced RCC. The company continues to evaluate the therapy in combination or as monothx across multiple settings & stages of RCC through its broad clinical program include 20 clinical studies & 4,000+ patients

Click here to­ read full press release/ article | Ref: Businesswire | Image: Shutterstock

The post Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021 first appeared on PharmaShots.